| Full Name | Dinh Le |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 845 S Main St, Willits, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215575642 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RPH81728 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dinh Le, 6949 Rio Tejo Way, Elk Grove, CA 95757-3433 Ph: (916) 549-2557 | Dinh Le, 845 S Main St, Willits, CA 95490-3915 Ph: (707) 459-5862 |
News Archive
Use of advanced treatment technologies for prostate cancer, such as intensity-modulated radiotherapy and robotic prostatectomy, has increased among men with low-risk disease, high risk of noncancer mortality, or both, a population of patients who are unlikely to benefit from these treatments, according to a study in the June 26 issue of JAMA.
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to women of Caucasian, Hispanic/Latina, Asian, and other ethnic backgrounds, according to a new study-the largest of its kind-published today in JAMA Cardiology by researchers from the Perelman school of Medicine at the University of Pennsylvania.
Oncotarget published "Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology" which reported that the authors comprehensively investigated miRNA-193a-3p's mode of action in a panel of human cancer cell lines, with a variety of genetic backgrounds, using 1B3, a synthetic microRNA mimic
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).
Drug company Eli Lilly has been given approval by the U.S. Food and Drug Administration (FDA) for its drug Gemzar to be used by women living with recurrent ovarian cancer.
› Verified 9 days ago
Lyra Cavada, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1730 S Main St, Willits, CA 95490 Phone: 707-459-0554 | |
Mr. Amir Ziaee, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 845 S Main St, Safeway Pharmacy 0965, Willits, CA 95490 Phone: 707-456-1790 Fax: 707-456-1794 | |
Dr. Frank A Braverman, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3 Marcela Dr, Willits, CA 95490 Phone: 707-456-3005 | |
Pooneh Ebrahimi, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 845 S Main St, Willits, CA 95490 Phone: 707-456-1790 | |
Ms. Heather Crystal Seargeant, BSP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 845 S Main St, Willits, CA 95490 Phone: 707-456-1790 Fax: 707-456-1794 | |
Amit Mathur, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 845 S Main St, Willits, CA 95490 Phone: 707-456-1790 |